GenOmics

News Release Salt Lake City, Apr 10, 2012 (GlobeNewswire via COMTEX) -- Myriad Genetics, Inc. (MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 1, 2012.

The Company will also host a conference call on Tuesday, May 1, 2012 at 4:30 P.M. Eastern to review the financial results. Participating on the call will be: Peter Meldrum, President and Chief Executive Officer, Mark Capone, President of Myriad Genetic Laboratories, Inc. and Jim Evans, Chief Financial Officer.

Media Release, 17 February 2012, Oxford, UK/FL, US.

Oxford Nanopore Technologies Ltd. today presented for the first time DNA sequence data using its novel nanopore 'strand sequencing' technique and proprietary high performance electronic devices GridION and MinION. These data were presented by Clive G Brown, Chief Technology Officer, who outlined the Company's pathway to a commercial product with highly disruptive features including ultra long read lengths, high throughput on electronic systems and real-time sequencing results. Oxford Nanopo...

New "BioReady™" On-Line Tool Offers Hope for Unemployed Manufacturing Workers Media Release, KITCHENER-WATERLOO, ON, Feb. 8, 2012 /CNW/ - BioTalent Canada, a national organization that addresses skills and human resources issues to ensure the bio-economy has access to job-ready people, was in Kitchener / Waterloo today launching an on-line skills transfer tool designed to assist unemployed manufacturing workers in gauging their readiness to work in biomanufacturing.

Speaking to a group of industry and business leaders in Kitchener / Waterloo today, Rob Henderson, Executive Director of BioTalent Canada, said that unemployed manufacturing workers are missing employment opportunities because they're unaware that their skills may match those of bio-manufacturers.

Adoption of Agricultural Biotechnology Increased Eight Percent Over Past YearMedia Release, WASHINGTON, D.C. (February 07, 2012) – Because of their tremendous environmental and economic benefits, farmers around the world continue to adopt genetically engineered (GE) crops according to a report released today by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA).

The ISAAA report, Global Status of Commercialized Biotech/GM Crops: 2011, says a record 16.7 million farmers in 29 countries are growing biotech crops on 395 million acres.

Media Release, Basel, 25 January 2012

Together with Illumina, Roche will strengthen its position in the Life Science and Diagnostics market, with complementary technologies in Genetics/Genomics research and routine diagnostics.Roche and Illumina’s combined capabilities and global reach will help accelerate the transition of sequencing into clinical and routine diagnostics.Roche intends to combine its existing Applied Science business with Illumina and move the business area’s headquarters to San Diego, California, USA. Roche also...

Media Release. Edmonton, Alberta - Innovative new drug therapies and health products that improve lives and generate new economic opportunities could soon become a reality as a result of a collaborative initiative announced today.

A federal investment of $500,000 through Western Economic Diversification Canada and an additional investment of $500,000 by Pfizer Canada will enable the Alberta Pfizer Collaboration Fund, now a $2.5 million initiative, to identify and support promising health care innovations with market potential.

Media Release, Ottawa, Dec. 7, 2011

A new study prepared for Genome Canada on the economic value of biotechnology forecasts a 9.4% average annual growth rate in the industry in the next 18 years, which translates into a total value of $144 billion by 2030.

The study by the Centre for the Study of Living Standards (CSLS), an Ottawa-based non-profit economic research organization, and authored by CSLS economist Ricardo de Avillez, says the significance of biotechnology extends beyond the value of economic goods and services to cover job creation, enhanced human health, reduced environmental damage, and greater production capacity.

Media Release, November 23,2011

The International Cooperation to Sequence the Atlantic Salmon Genome (ICSASG, the “Cooperation”) has awarded the Phase II contract for next-generation sequencing and analysis of the Atlantic salmon genome to the J. Craig Venter Institute (JCVI) in Rockville, Maryland. The JCVI will be sequencing the salmon genome using next-generation technologies, including assembly to integrate Sanger and next-generation sequence, and comparative genomics. This effort is expected to generate a high-quality...

Media Release, Nov.3, 2011

Today the New York Genome Center (NYGC) officially launched what will become one of the largest genomic facilities in North America, establishing an unprecedented, largescale collaborative venture in genomic medicine. Eleven of the country’s world-class private and academic medical centers form the foundation of NYGC, with support from the City of New York as well as private companies and foundations. Together, the partner institutions reach well over five million patients and are known as le...

Top-line results of the AKROBATS trial reveal greater adherence to statins for patients undergoing genetic testingAdditional study data presented at American Society of Human Genetics provide more insight into patient acceptance of pharmacogenetic testing and research participation Media Release, Oct 13, 2011

FRANKLIN LAKES, N.J. and MONTREAL, Oct. 13, 2011 /PRNewswire/ -- The Medco Research Institute, the research subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), and Quest Diagnostics (NYSE: DGX) announced their study showed a statistically significant increase in adherence to statin therapy over six months in patients receiving kinesin-like protein 6 (KIF6) gene testing, compared with those who did not. The AKROBATS (Additional KIF6 Risk Offers Better Adherence to Statins) trial is the f...

Supporting Data Presented at ASHG Annual Meeting Highlights New Argus Whole Genome Mapping Software Module and Faster, More Accurate Project Completion Capabilities

Media Relations.GAITHERSBURG, Md., Oct 13, 2011 (BUSINESS WIRE) -- OpGen, Inc. announced today the launch of Genome-Builder, a high performance software module that provides new, powerful capabilities for precision sequence assembly and significantly decreases the time and labor required for human, animal and plant genome sequence assembly. OpGen presented initial studies using Genome-Builder this week with its collaborators at the Sanger Institute during a New Methods Workshop at the joint m...

New service aimed at producing high-quality sequencing data from cancer genomes Media Release, MOUNTAIN VIEW, Calif., and MONTRÉAL, Canada — Oct. 12, 2011 — Complete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, introduced its new Cancer Sequencing Service today at the International Congress of Human Genetics (ICHG) and American Society of Human Genetics (ASHG) Annual Meeting in Montréal. Complete Genomics’ new Cancer Sequencing Service addresses the substantial cha...

Media Release, Washington, D.C. (September 16, 2011)

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the new initiatives announced by President Obama earlier today:

Université Laval Researcher Wins Genome Canada's Entrepreneurship Education in Genomics (EEG) CompetitionMedia Release

Québec City, September 15, 2011 – Genome Canada, in partnership with Génome Québec and Université Laval, is pleased to announce that Denis J. Garand, Associate Professor at the Department of Management of the Faculty of Administration, and his team have been awarded $1,12 million for the research project Boosting Entrepreneurial Skills and Training: BEST in Genomics!

Media Release, August 25th, 2011

New medical prototypes and diagnostic tools in commercialization pipelineVancouver, BC – Technology development in the life sciences sector received a much-needed boost with the announcement of five projects funded through Genome BC’s Proof of Concept (POC) Program. Genome BC’s program promises close to $9 million to accelerate the commercialization process for technological innovations in the life sciences. The program is intended to provide bridge funding to move innovations further down th...

Media Release, August 2, 2011

Research Demonstrates Potential of Novel Methods in Cancer Metabolism Research to Uncover New TargetsCAMBRIDGE, Mass.--(EON: Enhanced Online News)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication from Agios founder Lewis C. Cantley, Ph.D., and Agios advisor Matthew Vander Heiden, M.D., Ph.D., in the journal Nature Genetics that adds to evidence that...

Good interview with Dan Vorhaus about the Appeals Court decision last week in the Myriad Patent case. You'll find more audio and information at http://mendelspod.com/podcast

A video from a Lawline Seminar to give you some background on the Myriad gene patent dispute.

Big city hospitals have most of what they need on hand to handle emergencies in the Intensive Care Unit. Not so for small town and the rural hospitals out where I live, so when my conversation with Daniel Tasse turned to his company's role in ICU therapies, I steered the interview a little more in that direction.

Daniel is CEO and Chairman of Ikaria, a critical care company based in Clinton, New Jersey. The day before the interview he was elected to the Health section of the Biotechnology Industry Organization's Board of Directors.

On June 28th, Canada opened the Canadian Pavilion at BIO2011 in Washington, DC.

Canada has had a long running presence at the annual biotech get together and once again was the 2nd largest country presence on the exhibit floor.

Apart from the business partnering and announcements coming from the Canadian contingent, one of the hi-lites (for Canadian and International participants) is always the mini Tim Hortons inside the Canadian Cafe area. It was close to the business meeting area and it is a common site to see biotech executives or politicians talking over a Tim's cup of coffee.